share_log

Novavax | 4: Statement of changes in beneficial ownership of securities-Officer Kelly James Patrick

Novavax | 4: Statement of changes in beneficial ownership of securities-Officer Kelly James Patrick

諾瓦瓦克斯醫藥 | 4:持股變動聲明-高管 Kelly James Patrick
美股SEC公告 ·  01/04 06:43

Moomoo AI 已提取核心訊息

James Patrick Kelly, EVP, CFO and Treasurer of Novavax, is set to execute a planned stock transaction on 12/31/2024. Kelly will exercise options to acquire 35,000 shares of common stock at no cost, then immediately sell 16,906 shares at $8.04 per share to cover tax liabilities.The total value of the disposed shares amounts to $135,924.24. Following these transactions, Kelly's direct ownership in Novavax will increase to 32,602 shares. This pre-arranged transaction aligns with the company's executive compensation structure and tax obligation management practices.Investors should note that this future transaction is part of a planned executive stock option exercise and does not necessarily reflect the CFO's view on the company's current valuation or future prospects.
James Patrick Kelly, EVP, CFO and Treasurer of Novavax, is set to execute a planned stock transaction on 12/31/2024. Kelly will exercise options to acquire 35,000 shares of common stock at no cost, then immediately sell 16,906 shares at $8.04 per share to cover tax liabilities.The total value of the disposed shares amounts to $135,924.24. Following these transactions, Kelly's direct ownership in Novavax will increase to 32,602 shares. This pre-arranged transaction aligns with the company's executive compensation structure and tax obligation management practices.Investors should note that this future transaction is part of a planned executive stock option exercise and does not necessarily reflect the CFO's view on the company's current valuation or future prospects.
諾瓦瓦克斯醫藥的執行副總裁、財務長兼財務主管詹姆斯·帕特里克·凱利計劃於2024年12月31日執行一項預定的股票交易。凱利將行使期權,以零成本獲得35,000股普通股,然後立即以每股8.04美元的價格賣出16,906股以覆蓋稅務負擔。處置股份的總價值爲135,924.24美元。在這些交易完成後,凱利在諾瓦瓦克斯醫藥的直接持股將增至32,602股。這一預先安排的交易與公司的高管薪酬結構和稅務義務管理實踐一致。投資者應注意,此次未來交易是計劃中的高管股票期權行使,未必反映財務長對公司當前估值或未來前景的看法。
諾瓦瓦克斯醫藥的執行副總裁、財務長兼財務主管詹姆斯·帕特里克·凱利計劃於2024年12月31日執行一項預定的股票交易。凱利將行使期權,以零成本獲得35,000股普通股,然後立即以每股8.04美元的價格賣出16,906股以覆蓋稅務負擔。處置股份的總價值爲135,924.24美元。在這些交易完成後,凱利在諾瓦瓦克斯醫藥的直接持股將增至32,602股。這一預先安排的交易與公司的高管薪酬結構和稅務義務管理實踐一致。投資者應注意,此次未來交易是計劃中的高管股票期權行使,未必反映財務長對公司當前估值或未來前景的看法。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息